Regulation

ACCC clears merger of generic pharmaceutical firms Arrow and Apotex

The Australian Competition and Consumer Commission (ACCC) has decided not to oppose the merger of generic pharmaceutical companies Arrow and Apotex after finding that the transaction would not reduce competition in any market.

OBI Pharma’s OBI-3424 gets FDA orphan drug status to treat ALL

OBI Pharma’s small-molecule prodrug OBI-3424 has secured orphan drug designation (ODD) from the US Food and Drug Administration (FDA) for the treatment of acute lymphoblastic leukemia (ALL).

Cellectar gets FDA rare pediatric disease designation for CLR 131 to treat osteosarcoma

Cellectar Biosciences has secured rare pediatric disease designation (RPDD) from the US Food and Drug Administration (FDA) for its phospholipid drug conjugate (PDC) product candidate CLR 131 to treat rare pediatric cancer, osteosarcoma.

FDA approves Teva’s Ajovy for preventive treatment of migraine

Teva Pharmaceutical Industries has secured approval for its AJOVY (fremanezumab-vfrm) injection from the US Food and Drug Administration (FDA) for the preventive treatment of migraine in adults.

AstraZeneca secures FDA approval for Lumoxiti to treat hairy cell leukaemia

The US Food and Drug Administration (FDA) has approved AstraZeneca’s Lumoxiti (moxetumomab pasudotox-tdfk) for the treatment of adult patients with relapsed or refractory hairy cell leukaemia (HCL).

FDA approves subcutaneous formulation of Actemra to treat systemic juvenile idiopathic arthritis

Genentech, a member of the Roche Group, that the US Food and Drug Administration (FDA) has approved the subcutaneous (SC) formulation of Actemra (tocilizumab) for the treatment of active systemic juvenile idiopathic arthritis (SJIA) in patients two years of age and older.

Ironwood secures FDA fast track designation for heart drug praliciguat

Ironwood Pharmaceuticals has secured fast track designation from the US Food and Drug Administration (FDA) for praliciguat (IW-1973) for the treatment of patients with heart failure with preserved ejection fraction (HFpEF).

Shire’s Veyvondi secures approval in Europe for bleeding disorder

The European Commission (EC) has granted Marketing Authorization for VEYVONDI [vonicog alfa, recombinant von Willebrand factor] (rVWF), to treat bleeding events and treatment/prevention of surgical bleeding in adults (age 18 and older) with von Willebrand disease (VWD) when desmopressin (DDAVP) treatment alone is ineffective or not indicated.

Scottish Medicines Consortium accepts Sanofi’s Dupixent to treat moderate to severe atopic dermatitis

The Scottish Medicines Consortium (SMC) has accepted Dupixent (dupilumab) for restricted use within its existing marketing authorisation.